FLSM
CYTK icon

Frazier Life Sciences Management’s Cytokinetics CYTK Stock Holding History

Frazier Life Sciences Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98.8M Hold
1,159,879
– – 2.15% 13
2026
Q1 		$76.4M Buy
1,159,879
+225,237
+24% +$14.3M 1.97% 14
2025
Q4 		$59.4M Buy
934,642
+44,197
+5% +$2.75M 1.6% 19
2025
Q3 		$48.9M Buy
890,445
+335,714
+61% +$13.8M 1.47% 17
2025
Q2 		$18.3M Buy
+554,731
New +$19.3M 0.73% 28

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Frazier Life Sciences Management's CYTK Position: Q2 2026 in Review

Frazier Life Sciences Management held its Cytokinetics (CYTK) position steady in Q2 2026 at 1,159,879 shares worth $98.8M. The position accounts for 2.15% of the portfolio, ranked #13.

Frazier Life Sciences Management first reported a position in CYTK in Q2 2025 and has held it in 5 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Frazier Life Sciences Management held 1,159,879 shares of Cytokinetics worth $98.8M as of Q2 2026.
  • Frazier Life Sciences Management left its Cytokinetics share count unchanged in Q2 2026.
  • Cytokinetics made up 2.15% of Frazier Life Sciences Management's portfolio in Q2 2026, its #13 holding.
  • Frazier Life Sciences Management first reported a position in Cytokinetics in Q2 2025 and has held it in 5 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.